The Influence of Early Menopause on Cardiovascular Risk in Women with Rheumatoid Arthritis

Emily C. Pfeifer, Cynthia S. Crowson, Shreyasee Amin, Sherine E. Gabriel, and Eric L. Matteson

ABSTRACT. Objective. Early menopause is associated with an increased risk for developing rheumatoid arthritis (RA). The risk for cardiovascular disease (CVD) in women increases following menopause. Because RA is associated with an increased risk of CVD, this study was undertaken to determine whether early menopause affects the risk of developing CVD in women with RA.

Methods. A population-based inception cohort of 600 women with RA who fulfilled 1987 American College of Rheumatology criteria for RA between 1955 and 2007 and were age ≥ 45 years at diagnosis was assembled and followed. Age at menopause and duration of hormone replacement therapy, along with occurrence of CVD, was ascertained by review of medical records. Cox proportional hazard models compared women who underwent early menopause (natural or artificial menopause at age ≤ 45 yrs) to those within the cohort who did not undergo early menopause.

Results. Of 600 women, 79 experienced early menopause. Women who underwent early menopause were at significantly higher risk for developing CVD when compared to women who did not (HR 1.56; 95% CI 1.08–2.26).

Conclusion. The risk of CVD in women with RA was higher in those who experienced early menopause, and like other known risk factors should increase clinician concern for development of CVD in these patients. (First Release June 1 2014; J Rheumatol 2014;41:1270–5; doi:10.3899/jrheum.131234)

Key Indexing Terms:
RHEUMATOID ARTHRITIS MENOPAUSE CARDIOVASCULAR DISEASE

Rheumatoid arthritis (RA) has a female predominance and multiple investigations in recent years have suggested that a woman’s lifetime exposure to female sex hormones may play a role in the development and severity of the disease, with higher hormone exposure being associated with lower risk of disease development1,2,3,4. Specific evaluations of nulliparity, irregular menstrual cycles, breast feeding, oral contraceptive use, and hormone replacement therapy (HRT) have shed some further light on the role that hormones play in women with RA5,6,7,8,9. Studies have also shown that early menopause is associated with the development of RA10, although early menopause has paradoxically been associated with a milder form of the disease11.

It has also been suggested that lifetime exposure to female sex hormones may influence a woman’s risk of developing cardiovascular disease (CVD), with this risk being higher in women following menopause and increased even further by early menopause12. Finally, RA has been associated with an increased risk of cardiovascular events, specifically sudden cardiac death, with these events occurring earlier in life in those with RA compared to the general population13,14,15.

We investigated whether lower lifetime exposure to female sex hormones, with specific focus on age of menopause along with parity and hormone replacement exposure, is a predictor of CVD risk in women with RA. This was achieved by separately evaluating the relationship between early menopause (defined as natural or artificial menopause prior to age 45 yrs), parity, any hormone replacement exposure, and CVD outcomes in a population-based cohort study.

MATERIALS AND METHODS

Our study was conducted within the population of Olmsted County, Minnesota, USA. This population is well suited for longitudinal, population-based cohort studies of patients with RA because comprehensive medical records for all residents seeking any medical care for over 55 years are available. The medical records linkage system of the Rochester Epidemiology Project allows access to the complete inpatient and out-
Additional adjustment was also performed for traditional cardiovascular risk factors including smoking, HTN, diabetes mellitus, and high BMI. Factors assessed throughout followup (i.e., HRT, HTN, diabetes mellitus) were modeled as dichotomous time-dependent covariates. A subject’s status changed from unexposed to exposed at the time of the diagnosis of a particular risk factor during followup. Smoothing splines were used to examine potential nonlinear effects for parity. Person-year methods were used to estimate the rate of CVD according to early menopause status.

RESULTS

Our study included 600 women with RA age ≥ 45 years at diagnosis, of whom 79 experienced early menopause. The mean age at menopause in those who experienced early menopause was 40.9 ± 5.0 years; while in those who did not experience early menopause the mean age was 50.7 ± 2.8 years. Table 1 delineates the baseline characteristics of the study population. No differences in RA disease characteristics (RF positivity, ESR at RA incidence, or presence of erosions on radiographs in the first year after RA incidence) were found for those with and without early menopause. However, women who experienced early menopause were more likely to develop rheumatoid nodules during the first year following their diagnosis of RA (24% vs 13%). The number of women who experienced artificial menopause from surgery or secondary to radiation or chemical/medication exposure was significantly higher in those who underwent early menopause (42% vs 6%). This group was also more likely to have been taking HRT prior to diagnosis of RA (39% vs 28%). These factors were otherwise similar in both groups: mean age at which RA was diagnosed, other hormone-related variables, cardiovascular risk factors, RA disease characteristics, and prior CVD events.

Women with RA who did not experience early menopause were followed for an average of 11.9 years while women with RA who did experience early menopause were followed for an average of 11.0 years. Of the 521 women who did not undergo early menopause, 96 women without prior coronary heart disease experienced at least 1 coronary heart disease event during followup. Among women without prior events of each type, 117 developed heart failure, 62 experienced cerebrovascular events, and 40 experienced peripheral vascular disease events. Of the 79 women with RA who underwent early menopause, 26 experienced at least 1 coronary heart disease event, 19 experienced heart failure, 12 experienced cerebrovascular events, and 3 experienced peripheral vascular disease events during followup.

Overall, among women without prior CVD, 35 with early menopause and 170 without early menopause developed CVD during followup. As can be seen in Figure 1, the rate of any CVD is similar in women age 45 to 54 years who did not experience early menopause when compared to those who did; however, the rate of CVD increased more in women who experienced early menopause as age progressed.
Table 1. Characteristics of 600 women with rheumatoid arthritis (RA) according to presence or absence of early menopause.

<table>
<thead>
<tr>
<th>Characteristics</th>
<th>No Early Menopause, n = 521</th>
<th>Early Menopause*, n = 79</th>
<th>p</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mean age at index date, yrs (SD)</td>
<td>63.6 (11.7)</td>
<td>61.4 (11.0)</td>
<td>0.195</td>
</tr>
<tr>
<td>Mean age at menopause, yrs (SD)</td>
<td>50.7 (2.8)</td>
<td>40.9 (5.0)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>RF positivity, n (%)</td>
<td>331 (66)</td>
<td>50 (66)</td>
<td>0.97</td>
</tr>
<tr>
<td>ESR at RA incidence, mm/h</td>
<td>33.9 (24.6)</td>
<td>31.7 (24.5)</td>
<td>0.36</td>
</tr>
<tr>
<td>Presence of rheumatoid nodules in the first year after RA incidence, n (%)</td>
<td>70 (13)</td>
<td>19 (24)</td>
<td>0.013</td>
</tr>
<tr>
<td>Mean length of followup, yrs (SD)</td>
<td>11.9 (8.9)</td>
<td>11.0 (8.1)</td>
<td>—</td>
</tr>
<tr>
<td>Natural menopause, n (%)</td>
<td>474 (93)</td>
<td>46 (58)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Artificial menopause, n (%)</td>
<td>31 (6)</td>
<td>33 (42)</td>
<td>0.034</td>
</tr>
</tbody>
</table>

*Early menopause was defined as natural or artificial menopause at age ≤ 45 years. ** The difference between the natural menopause and the artificial menopause variables is the 5 patients who are still menstruating at RA incidence. RF: rheumatoid factor; ESR: erythrocyte sedimentation rate.

The association between characteristics influencing lifetime exposure to female sex hormones and CVD outcomes was assessed (Table 2). Women who underwent early menopause had a higher risk of developing general CVD, including coronary heart disease, heart failure, cerebrovascular disease, and/or peripheral vascular disease as described (HR 1.55, 95% CI 1.07–2.23). The risk of developing general CVD remained significant when the age of menopause was defined as the end of HRT for women with artificial menopause who started HRT at the time of artificial menopause (HR: 1.52, 95% CI 1.05–2.20). Of the 79 women who experienced early menopause, 26 were...
affected by this change in definition; however, only 9 of those women no longer qualified as early menopause.

The association between early menopause and the development of CVD did not differ among women with and without positive RF (interaction $p = 0.71$). Similarly, there were no differences in the associations between artificial menopause, parity, or any HRT exposure and the development of CVD among patients with and without positive RF.

After adjustment for CVD risk factors including smoking, high BMI, diabetes mellitus, and HTN, the association between early menopause and increased risk of CVD persisted (HR 1.56, 95% CI 1.08–2.26). The risk of developing CVD continued to be significant when the age of menopause was defined as the end of HRT for women with artificial menopause who started HRT at the time of artificial menopause (HR 1.53, 95% CI 1.06–2.23). As was found prior to adjustment for CVD risk factors, artificial menopause and exposure to hormone replacement at any time did not increase the risk of developing CVD.

CVD risk was also increased in women with higher parity (in linear analyses, HR 1.07 per 1 birth increase, 95% CI 1.01–1.14). However, there was a strong nonlinear relationship between parity and CVD outcomes, whereby the increased risk of CVD was detected only at very high values (> 7) of parity (Figure 2).

**DISCUSSION**

In our study, the overall risk for CVD events was increased in women with RA who experienced early menopause. The risk for individual cardiovascular outcomes of coronary heart disease, heart failure, and cerebrovascular disease were each increased, although none reached statistical significance.

In recent years, a number of studies have suggested that lower lifetime exposure to female sex hormones may play a role in the development and severity of RA in women. Decreased exposure to these hormones may also influence a woman’s risk of developing CVD. Further, RA has been associated with an increased risk of CVD events. In our study, we demonstrated that the risk of CVD in women with RA is significantly higher in those who experience early menopause.

It has long been recognized that there is a female predominance for RA. A variety of investigations have also suggested that gonadal hormones may play a role in the development and progression of RA. However, what is less understood is what the contribution of these sex hormones might be on development of CVD in RA.

Our findings are in agreement with other reports in the literature that there is an increase in CVD risk in women following menopause, and that this risk is further increased by early menopause. Indeed, women in the general population undergoing menopause prior to age 46 experience a 2-fold increased risk of future coronary heart disease or stroke events. Our investigations also show that CVD risk is higher as parity increases. These findings are incongruous with the hypothesis that higher lifetime exposure to female sex hormones decreases the risk of CVD. However, further analysis shows that there is a strong nonlinear relationship between parity and CVD outcomes, with the increased risk of CVD only being detected at very high values (> 7) of parity. This suggests that there may be a mechanism unrelated to hormone exposure leading to CVD in these women, especially in the setting of the other physiologic changes that take place during pregnancy. In view of the small numbers of women in this study of high parity, this observation is tentative and would require further study in cohorts with more women of high parity.

The relationships between lifetime exposure to female sex hormones and RA, hormone exposure and CVD, as well as CVD in relation to RA, have recently all been examined individually in several investigations. However, this study is among the first to specifically examine all 3 variables (sex hormone exposure, RA, and CVD) together and allowed us to conclude that early menopause, like other known CVD risk factors, increases the risk of CVD in women with RA.

Previous studies have suggested that RA may potentially contribute to early natural menopause. In an attempt to reduce this confounder, only women diagnosed with RA at ages older than 45 years were selected for our study. An additional strength of our study was the avoidance of selection bias with the population-based approach. There were also several limitations. First, the population of Olmsted County, Minnesota, is predominantly white; thus

---

**Table 2. Association between characteristics of female sex hormones and cardiovascular disease (CVD) outcomes in 600 women with rheumatoid arthritis (RA). Values in the table are HR (95% CI). All models adjusted for age (as the time scale) and calendar year of RA.**

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>Coronary Heart Disease</th>
<th>Heart Failure</th>
<th>Cerebrovascular Disease</th>
<th>Peripheral Vascular Disease</th>
<th>General CVD*</th>
</tr>
</thead>
<tbody>
<tr>
<td>Early menopause</td>
<td>1.42 (0.85, 2.39)</td>
<td>1.14 (0.69, 1.87)</td>
<td>1.41 (0.76, 2.62)</td>
<td>0.51 (0.16, 1.64)</td>
<td>1.55 (1.07, 2.23)</td>
</tr>
<tr>
<td>Artificial menopause</td>
<td>0.71 (0.33, 1.53)</td>
<td>0.82 (0.40, 1.69)</td>
<td>1.19 (0.54, 2.60)</td>
<td>0.24 (0.03, 1.74)</td>
<td>0.80 (0.46, 1.39)</td>
</tr>
<tr>
<td>Any pregnancy/birth</td>
<td>1.01 (0.65, 1.58)</td>
<td>0.92 (0.62, 1.36)</td>
<td>0.68 (0.41, 1.13)</td>
<td>0.92 (0.46, 1.82)</td>
<td>0.96 (0.68, 1.33)</td>
</tr>
<tr>
<td>Any HRT exposure</td>
<td>1.02 (0.68, 1.53)</td>
<td>0.72 (0.48, 1.07)</td>
<td>1.26 (0.77, 2.07)</td>
<td>0.84 (0.41, 1.72)</td>
<td>1.05 (0.77, 1.43)</td>
</tr>
</tbody>
</table>

* Includes coronary heart disease, heart failure, cerebrovascular disease, and peripheral vascular disease. HRT: hormone replacement therapy.
while our findings should be reflective of the majority of patients with RA seen in Western countries, the generalizability of our findings to more ethnically diverse populations may be limited. Second, the retrospective study design necessitates the use of information documented in medical records to uncover risk factors and outcomes. Therefore, risk factors and outcomes were dependent on physician observation and documentation. However, the use of the comprehensive population-based resources of Rochester Epidemiology Project likely minimized this bias. In addition, our analyses did not account for potential differences in RA disease severity or treatment regimens among women with and without early menopause. However, we did not find any significant differences in RA severity indicators measured at RA incidence. Further, the number of peripheral disease events observed in our study population was low, so the study was underpowered to definitively assess this outcome. Finally, no menopause data are yet available on a comparison cohort of subjects without RA. Because of this it was not possible to determine whether the relationship between early menopause and CVD differs in the RA population compared to the general population of Olmsted County.

As an observational study, it is only possible to report an association between RA, early menopause, and CVD. Our data suggest a significantly increased risk of CVD in women with RA who undergo early menopause. The underlying mechanism for this association remains unclear. Further studies will be needed to evaluate the role of female sex hormones in the increased inflammatory state of RA. It is possible that this mechanism is related both to RA disease severity and activity as well as other CVD risk factors.

Our findings demonstrate that the risk of developing CVD in women with RA is significantly higher in those who experience early menopause. It has previously been demonstrated that early menopause and RA each individually increase the risk of CVD in women. CVD has also been shown to occur earlier in those with RA. In aggregate, these findings suggest that early menopause, like other known risk factors in women with RA, should increase clinician concern for development of CVD in this population. These results suggest that optimal management of other known CVD risk factors may be especially important for women with both RA and early menopause. Further investigation is needed to determine the underlying mechanism by which female sex hormones act to protect against the development of CVD in women with RA.

REFERENCES


